Genetic variation and cognitive dysfunction in opioid-treated patients with cancer

Kurita, Geana Paula; Ekholm, Ola; Kaasa, Stein; Klepstad, Pål; Skorpen, Frank; Sjøgren, Per

Published in:
Brain and Behavior

DOI:
10.1002/brb3.471

Publication date:
2016

Document version
Publisher's PDF, also known as Version of record

Document license
CC BY

Citation for published version (APA):
Genetic variation and cognitive dysfunction in opioid-treated patients with cancer

Geana Paula Kurita1,2, Ola Ekholm3, Stein Kaasa4,5, Pal Klepstad6,7, Frank Skorpen8 & Per Sjøgren9,10

1Multidisciplinary Pain Centre, Department of Neuroanaesthesiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
2Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
3National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark
4Department of Oncology, Oslo University Hospital/University of Oslo, Norway
5European Palliative Care Research Centre, Faculty of Medicine Norwegian University of Science and Technology, Trondheim, Norway
6Department of Intensive Care Medicine, St Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
7Department of Circulation and Medical Imaging, Norwegian University of Science and Technology, Norway
8Department of Laboratory Medicine, Children’s and Women’s Health, Norwegian University of Science and Technology, Trondheim, Norway
9Section of Palliative Medicine, Department of Oncology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
10Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Keywords
Cognition, genes, neoplasms, opioids, polymorphism, single nucleotide

Correspondence
Geana Paula Kurita, Rigshospitalet Dept. 4111, Blegdamsvej 9, 2100 Copenhagen, Denmark. Fax: +45 3545 7157; E-mail: geana.kurita@regionh.dk

Received: 6 August 2015; Revised: 10 March 2016; Accepted: 11 March 2016

Brain and Behavior, 2016; 6(7), e00471, doi: 10.1002/brb3.471

Abstract

Background and purpose: The effects of single-nucleotide polymorphisms (SNPs) on the cognitive function of opioid-treated patients with cancer until now have not been explored, but they could potentially be related to poor functioning. This study aimed at identifying associations between SNPs of candidate genes, high opioid dose, and cognitive dysfunction. Methods: Cross-sectional multicenter study (European Pharmacogenetic Opioid Study, 2005–2008); 1586 patients; 113 SNPs from 41 genes. Inclusion criteria: cancer, age ≥18 year, opioid treatment, and available genetic data. Cognitive assessment by Mini-Mental State Examination (MMSE). Analyses: SNPs were rejected if violation of Hardy–Weinberg equilibrium (P < 0.0005), or minor allele frequency <5%; patients were randomly divided into discovery sample (2/3 for screening) and validation sample (1/3 for confirmatory test); false discovery rate of 10% for determining associations (Benjamini–Hochberg method). Co-dominant, dominant, and recessive models were analyzed by Kruskal–Wallis and Mann–Whitney tests. Results: In the co-dominant model significant associations (P < 0.05) between MMSE scores and SNPs in the HTR3E, TACR1, and IL6 were observed in the discovery sample, but the replication in the validation sample did not confirm it. Associations between MMSE scores among patients receiving ≥400 mg morphine equivalent dose/day and SNPs in TNFRSF1B, TLR5, HTR2A, and ADRA2A were observed, but they could not be confirmed in the validation sample. After correction for multiple testing, no SNPs were significant in the discovery sample. Dominant and recessive models also did not confirm significant associations. Conclusions: The findings did not support influence of those SNPs analyzed to explain cognitive dysfunction in opioid-treated patients with cancer.

Introduction

Patients with advanced cancer develop very frequently a wide range of symptoms, including cognitive dysfunction, which interfere with their daily life, health status, prognosis, compliance to treatment, social interactions, and quality of life. Causes for development of cognitive alterations are multiple and may be attributed to the cancer disease itself, comorbidities, and treatments including opioid therapy (Levine et al. 1978; Massie et al. 1983; Sjøgren 1997; Bruera et al. 1992; Baumgartner 2004; Kurita and Pimenta 2008). Some causes may be reversible or manageable; however, the knowledge and scientific exploration regarding this issue in patients with cancer is in its infancy.

Opioid treatment to manage cancer pain is the cornerstone in clinical practice and these drugs are highly recommended by WHO (1996) for this purpose. However, opioids have several adverse effects on the central nervous system, including cognitive dysfunction.
system and many of these effects are still unclear. Opioids can interfere with acquisition, processing, storage, and retrieval of information (Lawlor 2002). In addition to altering cognitive processes associated with memory, they can alter psychomotor function, mood, concentration, and other mental capabilities (Kurita et al. 2009).

In the past, questions related to opioid effects on cognition in patients with cancer did not represent a major point of concern. In palliative care, a possible reason for this was due to fast disease progression and short life expectancy. However, recently, an increased attention regarding cognitive functioning in palliative care as well as during the entire cancer trajectory has been noticed, although neuropsychological assessment of patients with cancer is a relatively new research area still based on rather limited scientific evidence. Thus, identification of mental alterations, specially mild and subtle alterations, are still frequently ignored and left undisclosed and treated (Inouye et al. 2001; Pisani et al. 2003).

We have formerly undertaken two studies in a multinational sample of opioid-treated patients with cancer, in which the cognitive effects of a wide range of variables were investigated (Kurita et al. 2011, 2015). They demonstrated that nearly 1/3 of opioid-treated patients with cancer presented possible or definite cognitive dysfunction and several factors, including opioid dose, were associated with the dysfunction (Kurita et al. 2011, 2015). Based on these series of studies, we considered that genetic factors could also be involved in the cognitive performance of opioid-treated patients with cancer and decided to proceed with analyzing potential candidate genes in the sample investigated in the previously mentioned studies.

Literature on associations between cognitive dysfunction and genetic variation in opioid-treated patients with cancer is practically nonexistent. In addition, knowledge on genetic influence on some specific cognitive disorders seems to be sparse (Flint 1999, 2001). Therefore, this study aimed at analyzing associations between single-nucleotide polymorphisms (SNPs) of candidate genes and cognitive functioning in opioid-treated patients with cancer. Moreover, keeping in mind that high opioid doses have previously been associated with cognitive dysfunction (Kurita et al. 2011, 2015), associations between SNPs in patients treated with high opioid doses and cognitive functioning were also investigated.

**Methods**

**Design and sample**

The sample analyzed in this study is derived from the European Pharmacogenetic Opioid Study (EPOS), which is a cross-sectional and multicenter investigation conducted in 11 countries during 2005–2008 (Klepstad et al. 2011). The original sample was composed by 2294 patients with cancer pain who were ≥18 year of age, had regular opioid treatment for at least 3 days for moderate or severe pain and able to speak the language used at the study center. In this study, we selected those with available genetic data and cognitive assessment by Mini-Mental State Examination (MMSE).

Research protocol was approved by local ethics committees (Regional Medical Research Ethics Committee, Central Norway Health Authority, Protocol reference number: 119-03, approved 27.09.03) and conducted in accordance with ethical standards of the Declaration of Helsinki. Written informed consent was obtained from all patients prior to their inclusion in the study.

**Genotyping procedures**

Blood samples were collected from the patients, handled, and stored in each center according to the study protocol, before shipment to the Department of Laboratory Medicine, Children’s and Women’s Health, Faculty of Medicine, Norwegian University of Science and Technology, where the genotyping analyses took place. DNA was extracted from EDTA-blood using the Gentra Puregene blood kit (Qiagen Science, Germantown, MD). Genotyping was performed by the SNPlex Genotyping System according to the supplier’s dry DNA protocol (Applied Biosystems, Foster City, CA). Capillary electrophoresis was carried out on an ABI 3730 48-capillary DNA analyzer (Applied Biosystems). SNPlex signals were analyzed using the Gene Mapper v.4.0 software (Applied Biosystems) followed by manual reading. Samples with signals that could not be discriminated from those of negative controls were excluded and treated as missing data. Two SNPs, rs4680 and rs1045642, were genotyped by TaqMan SNP allelic discrimination analysis, using an ABI 7900HT analyzer (Applied Biosystems).

In this study, selection of candidate genes and SNPs was restricted to a previous pool of genes analyzed regarding genetic variations and morphine efficacy (Klepstad et al. 2011). Those genes in the pool that according to the literature had any relation to cognitive function were selected for the present analyses.

**Cognitive function assessment**

Mini-Mental State Examination is an observer-rated brief battery of simple cognitive tests, which measure orientation to time and place, registration of words, attention, calculation, word recall, language, and visual construction. Scores range from 0 to 30. The cutoff between scores 26 and 24 means possible cognitive dysfunction and below
24 definite cognitive dysfunction (Folstein et al. 1984; Crum et al. 1993; Kurita et al. 2011).

Analyses

Statistical analyses were performed based on four steps:
1. The candidate SNPs were rejected if there was evidence of violation of Hardy–Weinberg equilibrium, which in the present data set was calculated as the difference between the observed and expected frequencies being \( P < 0.0005 \). They were also rejected if the minor allele frequency was <5%.
2. Patients were randomly divided into discovery sample for initial SNPs screening (discovery phase: 2/3 patients) and the validation sample for confirmatory test (replication phase: 1/3 patients). In order to confirm that SNPs is associated with cognitive function, the significant results found in the discovery sample should be replicated in the validation sample.
3. A false discovery rate of 10% was used for determining associations (Benjamini–Hochberg method), in which 10% of the positive results were expected to be false positives (Benjamini and Hochberg 1995).
4. The model chosen for the primary genetic analysis was the co-dominant model and associations were analyzed considering MMSE scores as a continuous variable and applying Kruskal–Wallis test. Secondary analyses were performed using dominant and recessive models, in which Mann–Whitney test was used. In addition, opioid daily doses were converted to equipotent mg of oral morphine as described in a previous study (Kurita et al. 2011) and further analyses were performed considering only patients receiving \( \geq 400 \) mg morphine equivalent dose/day due to the fact that association between cognitive dysfunction and opioid dose at this level was observed (Kurita et al. 2011). \( P \)-values below 0.05 were considered significant.

Results

Sample characteristics

A total of 1586 patients were analyzed. However, patients with missing MMSE scores were excluded (\( n = 217 \)). Most of them were patients from Norway (24.0%), Italy (19.9%), Germany (17.4%), and United Kingdom (17.2%). There were equal proportions of men (50.1%) and women (49.9%) and the majority were between 50 and 79 years old (76.5%). Approximately 80% of the sample was composed of inpatients, 23.8% were being treated with \( \geq 400 \) mg morphine equivalent dose/day and 27.6% had possible or definite cognitive dysfunction (Table 1).

Candidate genes

Forty-one candidate genes and 113 SNPs were analyzed. Out of them, six genes were excluded because they violated Hardy–Weinberg equilibrium or the minor allele presented a very low frequency. In addition, SNPs with more than 25% missing values were excluded from all analyses. Finally, 83 SNPs in 35 genes were analyzed in 1369 patients (Table 2).

Co-dominant model: Significant associations were observed between MMSE scores and the SNPs HTR3E rs6443950 (\( P = 0.003 \)), TACR1 rs881 (\( P = 0.006 \)), and IL6 rs2069835 (\( P = 0.019 \)) in the discovery sample, but the replication in the validation sample did not confirm the associations (Table 3). When only patients receiving \( \geq 400 \) mg morphine equivalent dose/day (\( n = 300 \)) were analyzed, significant associations between MMSE scores and SNPs TNFRSF1B rs3397, TLR5 rs5744168, HTR2A rs6311, and ADRA2A rs11195419 were observed in the discovery sample, but did not reach significance in the validation sample (Table 4). After correction for multiple testing, no SNPs were significant in the discovery sample.

Dominant model: Three significant associations were observed between MMSE scores and SNPs in the discovery sample (HTR3E rs6443950, IL6 rs2069835, and HTR2A rs6311), but the replication in the validation sample did not confirm the associations (Table 3). In patients receiving \( \geq 400 \) mg morphine equivalent dose/day, there were five significant SNPs in the discovery sample (TACR1 rs2160652, HTR2A rs6311, TLR5 rs5744168, ADRA2A rs11195419, TNFRSF1B rs3397), but none of them was significant in the validation sample (Table 4). After correction for multiple testing, no SNPs were significant in the discovery sample.

Recessive model: Three significant associations were observed between MMSE scores and SNPs in the discovery sample (TGFB2 rs1418553, GABBR2 rs2304389, TACR1 rs881), but the replication in the validation sample did not confirm the associations (Table 3). In patients receiving \( \geq 400 \) mg morphine equivalent dose/day, there four significant SNPs in the discovery sample (GABBR2 rs2779562, HTR3E rs6443950, IL6 rs2069835, ADRA2A rs553668), but none of them was significant in the validation sample (Table 4). After correction for multiple testing, no SNPs were significant in the discovery sample.

Discussion

In this study, a thorough exploration of 83 SNPs in 35 genes related to cognitive function was performed using
three current well-accepted genetic models (dominant, co-dominant and recessive) with discovery (discovery sample) and replication (validation sample) analyses (Lettre et al. 2007). Associations between SNPs and cognitive function in the total sample were explored, as well as considering that opioid can interfere on cognitive function, an analysis of SNPs and cognitive function in those patients receiving ≥ 400 mg morphine equivalent dose/day was also performed. Although some SNPs were associated with cognitive function in the discovery analysis, the replication did not confirm any associations. The absence of associations in this study may be due to one or more of the following possibilities: (1) the candidate genes of this study do not interfere with cognitive function; (2) cognitive dysfunction is influenced by polygenic genetic variations instead of isolated SNPs; (3) study limitations including influence of other variables (e.g., medication, comorbidities, general comprehensive measure of cognitive assessment as opposed to several instruments that investigate different specific domains), predefined genes, analysis of different opioids converted as morphine equivalents, and small sample size.

**Targeting the correct genes and analysis approach**

The genetic variability and associations with cognitive function is better described in the literature when focusing on specific mental diseases, in which there is a more straightforward identification of impairment and a direct relationship between genetic alteration (usually a mutation) and phenotype. The effect size of common SNPs is generally low and the majority is located in noncoding regions. Any effect from SNPs outside coding regions may be due to linkage disequilibrium with other functional SNPs with higher effect size, but very often at much lower frequency (Edwards et al. 2013).

Moreover, the selection of the analysis methods seems to play a fundamental role. The investigation of genetic

<table>
<thead>
<tr>
<th>Table 1. Patient’s characteristics (n = 1586).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Characteristics</strong></td>
</tr>
<tr>
<td>Country of residence</td>
</tr>
<tr>
<td>Denmark</td>
</tr>
<tr>
<td>Finland</td>
</tr>
<tr>
<td>Germany</td>
</tr>
<tr>
<td>Greece</td>
</tr>
<tr>
<td>Iceland</td>
</tr>
<tr>
<td>Italy</td>
</tr>
<tr>
<td>Lithuania</td>
</tr>
<tr>
<td>Norway</td>
</tr>
<tr>
<td>Sweden</td>
</tr>
<tr>
<td>Switzerland</td>
</tr>
<tr>
<td>United Kingdom</td>
</tr>
<tr>
<td>Gender</td>
</tr>
<tr>
<td>Men</td>
</tr>
<tr>
<td>Women</td>
</tr>
<tr>
<td>Age</td>
</tr>
<tr>
<td>18–39 year</td>
</tr>
<tr>
<td>40–49 year</td>
</tr>
<tr>
<td>50–59 year</td>
</tr>
<tr>
<td>60–69 year</td>
</tr>
<tr>
<td>70–79 year</td>
</tr>
<tr>
<td>≥80 year</td>
</tr>
<tr>
<td>No information</td>
</tr>
<tr>
<td>Setting</td>
</tr>
<tr>
<td>Palliative care unit / Hospice</td>
</tr>
<tr>
<td>General oncology ward</td>
</tr>
<tr>
<td>Surgical ward</td>
</tr>
<tr>
<td>Outpatient clinic</td>
</tr>
<tr>
<td>Cancer type</td>
</tr>
<tr>
<td>GI</td>
</tr>
<tr>
<td>Lung</td>
</tr>
<tr>
<td>Breast</td>
</tr>
<tr>
<td>Prostate</td>
</tr>
<tr>
<td>Female reproductive organs</td>
</tr>
<tr>
<td>Urologic</td>
</tr>
<tr>
<td>Hematologic</td>
</tr>
<tr>
<td>Head and neck</td>
</tr>
<tr>
<td>Sarcoma</td>
</tr>
<tr>
<td>Pancreatic</td>
</tr>
<tr>
<td>Skin</td>
</tr>
<tr>
<td>Other or more than one type</td>
</tr>
<tr>
<td>Metastasis CNS</td>
</tr>
<tr>
<td>Yes</td>
</tr>
<tr>
<td>No</td>
</tr>
<tr>
<td>Karnofsky performance</td>
</tr>
<tr>
<td>Able to carry on normal activity/work</td>
</tr>
<tr>
<td>Unable to work</td>
</tr>
<tr>
<td>Unable to care for self</td>
</tr>
<tr>
<td>No information</td>
</tr>
<tr>
<td>Type of opioid</td>
</tr>
<tr>
<td>Morphine only</td>
</tr>
<tr>
<td>Fentanyl only</td>
</tr>
<tr>
<td>Oxycodone only</td>
</tr>
<tr>
<td>Hydromorphone only</td>
</tr>
<tr>
<td>Buprenorphine</td>
</tr>
</tbody>
</table>

(Continued)
<table>
<thead>
<tr>
<th>Gene (gene product)</th>
<th>Link</th>
<th>Genotype Frequencies (n = 1586 patients)</th>
</tr>
</thead>
</table>
| **COMT** (catechol-O-methyltransferase) | Cognitive decline in late life (Fiocco et al. 2010) | rs5993882 T>G 772 (58.8) 469 (35.7) 71 (5.4)rs4646312 T>C 467 (35.7) 630 (48.2) 210 (16.1)rs6277 C>A 393 (30.8) 694 (52.9) 200 (15.3)rs4680 A>G 360 (26.8) 683 (50.9) 299 (22.3)rs20209171 A>G 365 (28.7) 638 (48.2) 271 (20.1)rs11195419 C>A 963 (77.9) 253 (20.5) 20 (1.6)rs1554929 A>G 377 (28.3) 605 (45.3) 262 (19.5)rs324026 T>C 545 (44.1) 548 (43.4) 154 (12.5)rs1195419 C>A 963 (77.9) 253 (20.5) 20 (1.6)rs1554929 A>G 377 (28.3) 605 (45.3) 262 (19.5)rs324026 T>C 545 (44.1) 548 (43.4) 154 (12.5)rs5993882 T>G 772 (58.8) 469 (35.7) 71 (5.4)rs4646312 T>C 467 (35.7) 630 (48.2) 210 (16.1)rs6277 C>A 393 (30.8) 694 (52.9) 200 (15.3)rs4680 A>G 360 (26.8) 683 (50.9) 299 (22.3)rs20209171 A>G 365 (28.7) 638 (48.2) 271 (20.1)rs11195419 C>A 963 (77.9) 253 (20.5) 20 (1.6)rs1554929 A>G 377 (28.3) 605 (45.3) 262 (19.5)rs324026 T>C 545 (44.1) 548 (43.4) 154 (12.5)rs5993882 T>G 772 (58.8) 469 (35.7) 71 (5.4)rs4646312 T>C 467 (35.7) 630 (48.2) 210 (16.1)rs6277 C>A 393 (30.8) 694 (52.9) 200 (15.3)rs4680 A>G 360 (26.8) 683 (50.9) 299 (22.3)rs20209171 A>G 365 (28.7) 638 (48.2) 271 (20.1)rs11195419 C>A 963 (77.9) 253 (20.5) 20 (1.6)rs1554929 A>G 377 (28.3) 605 (45.3) 262 (19.5)rs324026 T>C 545 (44.1) 548 (43.4) 154 (12.5)rs5993882 T>G 772 (58.8) 469 (35.7) 71 (5.4)rs4646312 T>C 467 (35.7) 630 (48.2) 210 (16.1)rs6277 C>A 393 (30.8) 694 (52.9) 200 (15.3)rs4680 A>G 360 (26.8) 683 (50.9) 299 (22.3)rs20209171 A>G 365 (28.7) 638 (48.2) 271 (20.1)rs11195419 C>A 963 (77.9) 253 (20.5) 20 (1.6)rs1554929 A>G 377 (28.3) 605 (45.3) 262 (19.5)rs324026 T>C 545 (44.1) 548 (43.4) 154 (12.5)rs5993882 T>G 772 (58.8) 469 (35.7) 71 (5.4)rs4646312 T>C 467 (35.7) 630 (48.2) 210 (16.1)rs6277 C>A 393 (30.8) 694 (52.9) 200 (15.3)rs4680 A>G 360 (26.8) 683 (50.9) 299 (22.3)rs20209171 A>G 365 (28.7) 638 (48.2) 271 (20.1)rs11195419 C>A 963 (77.9) 253 (20.5) 20 (1.6)rs1554929 A>G 377 (28.3) 605 (45.3) 262 (19.5)rs324026 T>C 545 (44.1) 548 (43.4) 154 (12.5)rs5993882 T>G 772 (58.8) 469 (35.7) 71 (5.4)rs4646312 T>C 467 (35.7) 630 (48.2) 210 (16.1)rs6277 C>A 393 (30.8) 694 (52.9) 200 (15.3)rs4680 A>G 360 (26.8) 683 (50.9) 299 (22.3)rs20209171 A>G 365 (28.7) 638 (48.2) 271 (20.1)rs11195419 C>A 963 (77.9) 253 (20.5) 20 (1.6)rs1554929 A>G 377 (28.3) 605 (45.3) 262 (19.5)rs324026 T>C 545 (44.1) 548 (43.4) 154 (12.5)rs5993882 T>G 772 (58.8) 469 (35.7) 71 (5.4)rs4646312 T>C 467 (35.7) 630 (48.2) 210 (16.1)rs6277 C>A 393 (30.8) 694 (52.9) 200 (15.3)rs4680 A>G 360 (26.8) 683 (50.9) 299 (22.3)rs20209171 A>G 365 (28.7) 638 (48.2) 271 (20.1)rs11195419 C>A 963 (77.9) 253 (20.5) 20 (1.6)rs1554929 A>G 377 (28.3) 605 (45.3) 262 (19.5)rs324026 T>C 545 (44.1) 548 (43.4) 154 (12.5)rs5993882 T>G 772 (58.8) 469 (35.7) 71 (5.4)rs4646312 T>C 467 (35.7) 630 (48.2) 210 (16.1)rs6277 C>A 393 (30.8) 694 (52.9) 200 (15.3)rs4680 A>G 360 (26.8) 683 (50.9) 299 (22.3)rs20209171 A>G 365 (28.7) 638 (48.2) 271 (20.1)rs11195419 C>A 963 (77.9) 253 (20.5) 20 (1.6)rs1554929 A>G 377 (28.3) 605 (45.3) 262 (19.5)rs324026 T>C 545 (44.1) 548 (43.4) 154 (12.5)
<table>
<thead>
<tr>
<th>Gene (gene product)</th>
<th>Link</th>
<th>Polymorphism</th>
<th>Alleles</th>
<th>Genotypes; n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HTR3A (5-hydroxytryptamine receptor 3A, ionotropic)</td>
<td></td>
<td>rs1062613&lt;sup&gt;1&lt;/sup&gt;, rs2276302&lt;sup&gt;1&lt;/sup&gt;, rs1176719&lt;sup&gt;1&lt;/sup&gt;, rs1176713&lt;sup&gt;1&lt;/sup&gt;</td>
<td>G&gt;A</td>
<td>877 (70.6) 331 (26.7) 34 (2.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs1176744</td>
<td>T&gt;C</td>
<td>461 (35.9) 628 (48.9) 196 (15.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs7943062</td>
<td>G&gt;A</td>
<td>897 (70.2) 348 (27.2) 33 (2.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs2276307&lt;sup&gt;1&lt;/sup&gt;, rs3782025&lt;sup&gt;1&lt;/sup&gt;</td>
<td>T&gt;G</td>
<td>549 (44.2) 579 (46.6) 114 (9.2)</td>
</tr>
<tr>
<td>HTR3B (5-hydroxytryptamine receptor 3B, ionotropic)</td>
<td>Learning and memory (Meneses 1999)</td>
<td>rs11214763</td>
<td>G&gt;A</td>
<td>877 (70.6) 331 (26.7) 34 (2.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs1672717</td>
<td>T&gt;C</td>
<td>461 (35.9) 628 (48.9) 196 (15.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs7943062</td>
<td>G&gt;A</td>
<td>897 (70.2) 348 (27.2) 33 (2.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs1176744</td>
<td>T&gt;G</td>
<td>549 (44.2) 579 (46.6) 114 (9.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs2276307&lt;sup&gt;1&lt;/sup&gt;, rs3782025&lt;sup&gt;1&lt;/sup&gt;</td>
<td>T&gt;G</td>
<td>549 (44.2) 579 (46.6) 114 (9.2)</td>
</tr>
<tr>
<td>HTR3C (5-hydroxytryptamine receptor 3C, ionotropic)</td>
<td>Learning and memory (Meneses 1999)</td>
<td>rs6766410&lt;sup&gt;1&lt;/sup&gt;, rs807362&lt;sup&gt;1&lt;/sup&gt;, rs807670&lt;sup&gt;1&lt;/sup&gt;, rs808122&lt;sup&gt;1&lt;/sup&gt;</td>
<td>G&gt;A</td>
<td>897 (70.2) 348 (27.2) 33 (2.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs11214763</td>
<td>G&gt;A</td>
<td>877 (70.6) 331 (26.7) 34 (2.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs1672717</td>
<td>T&gt;C</td>
<td>461 (35.9) 628 (48.9) 196 (15.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs7943062</td>
<td>G&gt;A</td>
<td>897 (70.2) 348 (27.2) 33 (2.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs1176744</td>
<td>T&gt;G</td>
<td>549 (44.2) 579 (46.6) 114 (9.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs2276307&lt;sup&gt;1&lt;/sup&gt;, rs3782025&lt;sup&gt;1&lt;/sup&gt;</td>
<td>T&gt;G</td>
<td>549 (44.2) 579 (46.6) 114 (9.2)</td>
</tr>
<tr>
<td>HTR3D (5-hydroxytryptamine receptor 3D, ionotropic)</td>
<td>Learning and memory (Meneses 1999)</td>
<td>rs6792482, rs939334&lt;sup&gt;1&lt;/sup&gt;, rs7621975&lt;sup&gt;1&lt;/sup&gt;</td>
<td>T&gt;C</td>
<td>386 (31.1) 628 (50.6) 227 (18.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs6443950</td>
<td>T&gt;A</td>
<td>528 (40.1) 629 (47.8) 160 (12.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs7627615&lt;sup&gt;1&lt;/sup&gt;, rs4912522&lt;sup&gt;1&lt;/sup&gt;</td>
<td>G&gt;A</td>
<td>428 (32.5) 656 (49.8) 233 (17.7)</td>
</tr>
<tr>
<td>HTR4 (5-hydroxytryptamine receptor 4, G protein-coupled)</td>
<td>Learning and memory (Meneses 1999)</td>
<td>rs6443950</td>
<td>T&gt;A</td>
<td>528 (40.1) 629 (47.8) 160 (12.1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs7627615&lt;sup&gt;1&lt;/sup&gt;, rs4912522&lt;sup&gt;1&lt;/sup&gt;</td>
<td>G&gt;A</td>
<td>428 (32.5) 656 (49.8) 233 (17.7)</td>
</tr>
<tr>
<td>HHR1 (histamine receptor H1)</td>
<td>Learning and memory in mice (Dai et al. 2007)</td>
<td>rs2606731&lt;sup&gt;1&lt;/sup&gt;, rs346070&lt;sup&gt;1&lt;/sup&gt;</td>
<td>G&gt;A</td>
<td>493 (39.4) 578 (46.2) 179 (14.3)</td>
</tr>
<tr>
<td>ADRB1 (adrenoeceptor beta 1)</td>
<td>Alzheimer disease (Bulide et al. 2004)</td>
<td>rs1801253&lt;sup&gt;1&lt;/sup&gt;</td>
<td>G&gt;A</td>
<td>493 (39.4) 578 (46.2) 179 (14.3)</td>
</tr>
<tr>
<td>ADRB2 (adrenoeceptor beta 2)</td>
<td>IQ, memory and learning in young and elderly (Bochdanovits et al. 2009)</td>
<td>rs1042714&lt;sup&gt;1&lt;/sup&gt;, rs1042717&lt;sup&gt;1&lt;/sup&gt;</td>
<td>G&gt;A</td>
<td>493 (39.4) 578 (46.2) 179 (14.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs1042717&lt;sup&gt;1&lt;/sup&gt;</td>
<td>G&gt;A</td>
<td>788 (64.5) 374 (30.6) 59 (4.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs1800888&lt;sup&gt;2&lt;/sup&gt;, rs1042719&lt;sup&gt;1&lt;/sup&gt;</td>
<td>G&gt;A</td>
<td>788 (64.5) 374 (30.6) 59 (4.8)</td>
</tr>
<tr>
<td>GABBR2 (gamma-aminobutyric acid (GABA) B receptor, 2)</td>
<td>Epilepsy (Wang et al. 2008)</td>
<td>rs10818743</td>
<td>T&gt;G</td>
<td>858 (67.8) 378 (29.9) 29 (2.3)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs2304389&lt;sup&gt;1&lt;/sup&gt;</td>
<td>G&gt;A</td>
<td>918 (71.4) 327 (25.4) 41 (3.2)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs1435252&lt;sup&gt;1&lt;/sup&gt;</td>
<td>C&gt;T</td>
<td>625 (49.2) 534 (42.0) 111 (8.7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs2779562&lt;sup&gt;1&lt;/sup&gt;</td>
<td>T&gt;C</td>
<td>321 (25.0) 646 (50.4) 315 (24.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs2808536&lt;sup&gt;1&lt;/sup&gt;</td>
<td>C&gt;A</td>
<td>591 (49.3) 516 (43.1) 91 (7.6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>rs570138&lt;sup&gt;1&lt;/sup&gt;</td>
<td>C&gt;T</td>
<td>787 (61.6) 424 (33.2) 67 (5.2)</td>
</tr>
<tr>
<td>Gene (gene product)</td>
<td>Link</td>
<td>Polymorphism</td>
<td>Alleles</td>
<td>Genotypes, n (%)</td>
</tr>
<tr>
<td>---------------------</td>
<td>------</td>
<td>--------------</td>
<td>---------</td>
<td>-----------------</td>
</tr>
<tr>
<td><strong>IL1R1</strong> (interleukin 1 receptor, type I)</td>
<td>General cognitive performance (Benke et al. 2011)</td>
<td>rs3750344</td>
<td>A&gt;G</td>
<td>848 (67.4) 248 (19.7) 162 (12.9)</td>
</tr>
<tr>
<td><strong>IL1A</strong> (interleukin 1 alpha)</td>
<td>General cognitive performance (Benke et al. 2011)</td>
<td>rs2228139</td>
<td>C&gt;G</td>
<td>1110 (88.3) 141 (11.2) 6 (0.5)</td>
</tr>
<tr>
<td><strong>IL1B</strong> (interleukin 1 beta)</td>
<td>General cognitive performance (Benke et al. 2011; Sasayama et al. 2011)</td>
<td>rs17561</td>
<td>G&gt;T</td>
<td>642 (50.5) 515 (40.5) 114 (9.0)</td>
</tr>
<tr>
<td><strong>IL1A</strong> (interleukin 1 alpha)</td>
<td>General cognitive performance (Benke et al. 2011; Sasayama et al. 2011)</td>
<td>rs1143634</td>
<td>T&gt;C</td>
<td>711 (56.6) 464 (36.9) 82 (6.5)</td>
</tr>
<tr>
<td><strong>IL4</strong> (interleukin 4)</td>
<td>General cognitive performance (Gorelick 2010; Simen et al. 2011; Goldstein et al. 2014)</td>
<td>rs1143627</td>
<td>T&gt;G</td>
<td>551 (43.3) 577 (45.3) 145 (11.4)</td>
</tr>
<tr>
<td><strong>IL6</strong> (interleukin 6)</td>
<td>Delirium (van Munster et al. 2011)</td>
<td>rs2069853</td>
<td>T&gt;C</td>
<td>1062 (86.6) 155 (12.6) 9 (0.7)</td>
</tr>
<tr>
<td><strong>CXL8</strong> (chemokine (C-X-C motif) ligand 8)</td>
<td>Delirium (van Munster et al. 2011)</td>
<td>rs4073</td>
<td>T&gt;A</td>
<td>357 (28.9) 600 (48.3) 280 (22.6)</td>
</tr>
<tr>
<td><strong>IL10</strong> (interleukin 10)</td>
<td>Neurodegeneration (Arosio et al. 2010)</td>
<td>rs1800872</td>
<td>C&gt;A</td>
<td>728 (57.7) 461 (36.5) 73 (5.8)</td>
</tr>
<tr>
<td><strong>IL12B</strong> (interleukin 12B)</td>
<td>Inflammation impact on cognitive function (Goldstein et al. 2014)</td>
<td>rs1800896</td>
<td>A&gt;G</td>
<td>398 (31.3) 577 (45.4) 297 (23.3)</td>
</tr>
<tr>
<td><strong>IL13</strong> (interleukin 13)</td>
<td>Inflammation impact on cognitive function (Goldstein et al. 2014)</td>
<td>rs1368439</td>
<td>T&gt;G</td>
<td>836 (65.7) 397 (31.2) 39 (3.1)</td>
</tr>
<tr>
<td><strong>IL18</strong> (interleukin 18)</td>
<td>Neurodegeneration (Alboni et al. 2010)</td>
<td>rs1800925</td>
<td>C&gt;T</td>
<td>836 (67.2) 364 (29.3) 44 (3.5)</td>
</tr>
<tr>
<td><strong>IGF1</strong> (insulin-like growth factor 1)</td>
<td>Cognitive dysfunction (Licht et al. 2014)</td>
<td>rs360729</td>
<td>T&gt;A</td>
<td>609 (48.6) 529 (42.2) 115 (9.2)</td>
</tr>
<tr>
<td><strong>IFNGR1</strong> (interferon gamma receptor 1)</td>
<td>Depression, cognitive dysfunction related to aging (Oxenkrug 2011)</td>
<td>rs5744256</td>
<td>T&gt;C</td>
<td>732 (57.8) 464 (36.7) 70 (5.5)</td>
</tr>
<tr>
<td><strong>IFNG</strong> (interferon gamma)</td>
<td>Depression, cognitive dysfunction related to aging (Oxenkrug 2011)</td>
<td>rs2043055</td>
<td>A&gt;G</td>
<td>526 (40.9) 585 (45.5) 176 (13.7)</td>
</tr>
<tr>
<td><strong>NFKB1A</strong> (nuclear factor of kappa light-chain gene)</td>
<td>Neuroplasticity-related genes, age and cognitive deficit (Li et al. 2015)</td>
<td>rs1946519</td>
<td>C&gt;A</td>
<td>458 (36.3) 592 (46.9) 213 (16.9)</td>
</tr>
<tr>
<td><strong>IGF1</strong> (insulin-like growth factor 1)</td>
<td>Cognitive dysfunction (Licht et al. 2014)</td>
<td>rs11111272</td>
<td>C&gt;G</td>
<td>648 (51.5) 514 (40.8) 97 (7.7)</td>
</tr>
<tr>
<td><strong>IFNR1</strong> (interferon gamma receptor 1)</td>
<td>Depression, cognitive dysfunction related to aging (Oxenkrug 2011)</td>
<td>rs10735380</td>
<td>A&gt;G</td>
<td>651 (52.2) 503 (40.3) 94 (7.5)</td>
</tr>
<tr>
<td><strong>IFNG</strong> (interferon gamma)</td>
<td>Depression, cognitive dysfunction related to aging (Oxenkrug 2011)</td>
<td>rs7749390</td>
<td>A&gt;G</td>
<td>441 (35.2) 621 (49.5) 192 (15.3)</td>
</tr>
<tr>
<td><strong>NFKB1A</strong> (nuclear factor of kappa light-chain gene)</td>
<td>Neuroplasticity-related genes, age and cognitive deficit (Li et al. 2015)</td>
<td>rs696</td>
<td>G&gt;A</td>
<td>501 (39.7) 598 (47.3) 164 (13.0)</td>
</tr>
</tbody>
</table>

(Continued)
Table 2. Continued.

<table>
<thead>
<tr>
<th>Gene (gene product)</th>
<th>Link</th>
<th>Polymorphism</th>
<th>Alleles</th>
<th>Genotypes; n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>enhancer in B cells inhibitor, alpha)</td>
<td></td>
<td>rs1130864</td>
<td>C&gt;T</td>
<td>574 (45.7) 549 (43.7) 133 (10.6)</td>
</tr>
<tr>
<td>CRP (C-reactive protein, pentaxin-related)</td>
<td>Cognitive decline (Mooijaart et al. 2011)</td>
<td>rs1800947</td>
<td>G&gt;C</td>
<td>1090 (87.6) 149 (12.0) 6 (0.5)</td>
</tr>
<tr>
<td>TNF (tumor necrosis factor)</td>
<td>Attention, mental rotation (Beste et al. 2010)</td>
<td>rs1799964</td>
<td>T&gt;C</td>
<td>793 (63.0) 408 (32.4) 58 (4.6)</td>
</tr>
<tr>
<td>TNFRSF1A (tumor necrosis factor receptor superfamily member 1A)</td>
<td>Attention, mental rotation (Beste et al. 2010)</td>
<td>rs1800629</td>
<td>G&gt;A</td>
<td>883 (70.1) 339 (26.9) 38 (3.0)</td>
</tr>
<tr>
<td>TNFRSF1B (tumor necrosis factor receptor superfamily member 1B)</td>
<td>Attention, mental rotation (Beste et al. 2010)</td>
<td>rs767455</td>
<td>T&gt;C</td>
<td>428 (34.3) 597 (47.8) 224 (17.9)</td>
</tr>
<tr>
<td>TGFβ1 (transforming growth factor beta 1)</td>
<td>Neurocognitive alterations (Loeys et al. 2005)</td>
<td>rs4149570</td>
<td>G&gt;T</td>
<td>465 (36.5) 589 (46.3) 219 (17.2)</td>
</tr>
<tr>
<td>TGFβ2 (transforming growth factor beta 2)</td>
<td>Neurocognitive alterations (Loeys et al. 2005)</td>
<td>rs1799964</td>
<td>T&gt;C</td>
<td>408 (32.4) 574 (45.7) 133 (10.6)</td>
</tr>
<tr>
<td>TLR2 (toll-like receptor 2)</td>
<td>Neurodegeneration (Crack and Bray 2007)</td>
<td>rs4696480</td>
<td>A&gt;G</td>
<td>645 (51.1) 532 (42.2) 84 (6.7)</td>
</tr>
<tr>
<td>TLR4 (toll-like receptor 4)</td>
<td>Neurodegeneration (Crack and Bray 2007)</td>
<td>rs3804100</td>
<td>T&gt;A</td>
<td>325 (25.5) 633 (49.7) 315 (24.7)</td>
</tr>
<tr>
<td>TLR5 (toll-like receptor 5)</td>
<td>Neurodegeneration (Crack and Bray 2007)</td>
<td>rs4967902</td>
<td>C&gt;T</td>
<td>1091 (86.7) 164 (13.0) 3 (0.2)</td>
</tr>
<tr>
<td>GCDH (glutaryl-CoA dehydrogenase)</td>
<td>Neurodevelopment in mice (Busanello et al. 2013)</td>
<td>rs11085824</td>
<td>A&gt;G</td>
<td>481 (38.5) 603 (48.3) 165 (13.2)</td>
</tr>
</tbody>
</table>

Link refers to studies that analyzed or suggested a relation between the gene and cognitive function.
The absolute numbers and the frequencies of genotypes are written in the following order: homozygous for the most common allele – heterozygotes – homozygous for the minor allele.

1Excluded due to >25% missing values.

2Single-nucleotide polymorphisms with allele frequency <5% or with Hardy-Weinberg equilibrium test P-values < 0.0005 were excluded.
variability in the phenotype of interest is usually based on two approaches. In the first approach, a selected number of genetic variations are tested for single associations founded in hypotheses regarding biological functions of candidate genes (candidate gene design). In the second, many random SNPs are tested for associations with phenotype under a statistical correction for multiple hypotheses testing based on the proposition that cognitive traits are controlled by multiple genes (genome-wide association study) (Rietveld et al. 2014). Until now, these approaches on cognitive function have failed to replicate findings or have found small significant associations (Chabris et al. 2012; Payton 2009; Davies et al. 2011; Benyamin et al. 2014).

In the candidate gene design, most effects of genes on cognitive processing are often analyzed by methods of genetic linkage and association, which result in a statistical modeling that examines relations between a part of the chromosome and a phenotype (Flint 1999). However, it has been suggested that cognitive impairment does not result from a mutation in a single gene and that variations regarding intelligence quotients involve combinations of a number of genes (polygenic genetic basis) that influence, for example, impairment (Nokelainen and Flint 2002). Thus, genome-wide studies have demonstrated the influence of polygenic variations on cognitive function, psychiatric diseases, and dementing processes (Bulayeva et al. 2015).

Meta-analysis of population cohorts is another approach in the genome-wide studies, which can include polygenic analyses. However, the studies showed that the SNPs assessed have accounted for a very small portion (2%) of the phenotypic variance (Rietveld et al. 2013; Davies et al. 2015). Other methods to refine genetic analysis include analysis of subgroups with common characteristics pertinent to specific diseases (Debette et al. 2015). Therefore, the genome-wide studies have indicated that cognitive dysfunction may result from combination of genetic variants rather than individual effect of a SNP. However, combination of genetic variants often requires large samples in order to successfully replicate findings, estimate predictors by polygenic analyses (Dudbridge 2013), and identify 1–2% of genetic variability. It is a notion for power calculation and estimates of the possible effect sizes of future studies.

### Candidate genes for opioid effects and consequences for cognitive function

Previous knowledge on the association between high opioid doses and cognitive dysfunction (Kurita et al. 2011), and a possible connection with genes that may have influence on

<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP</th>
<th>Minor allele</th>
<th>Discovery sample (n = 911)</th>
<th>Validation sample (n = 458)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Co-dominant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HTR3E</td>
<td>rs6443950</td>
<td>A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AA</td>
<td>AT</td>
<td>TT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>111</td>
<td>402</td>
<td>361</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CC</td>
<td>CG</td>
<td>GG</td>
</tr>
<tr>
<td>TACR1</td>
<td>rs881</td>
<td>C</td>
<td>28</td>
<td>244</td>
</tr>
<tr>
<td>IL6</td>
<td>rs2069835</td>
<td>C</td>
<td>3</td>
<td>52</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6</td>
<td>103</td>
<td>708</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP</th>
<th>Minor allele</th>
<th>Discovery sample (n = 911)</th>
<th>Validation sample (n = 458)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dominant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HTR3E</td>
<td>rs6443950</td>
<td>A</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>AA+AT</td>
<td>TT</td>
<td>AA+AT</td>
</tr>
<tr>
<td></td>
<td></td>
<td>763</td>
<td>111</td>
<td>28</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TT+CT</td>
<td>CC</td>
<td>TT+CT</td>
</tr>
<tr>
<td>IL6</td>
<td>rs2069835</td>
<td>C</td>
<td>811</td>
<td>6</td>
</tr>
<tr>
<td>HTR2A</td>
<td>rs6311</td>
<td>T</td>
<td>601</td>
<td>273</td>
</tr>
<tr>
<td>TGF2</td>
<td>rs1418553</td>
<td>T</td>
<td>765</td>
<td>83</td>
</tr>
<tr>
<td>GABBR2</td>
<td>rs2304389</td>
<td>A</td>
<td>243</td>
<td>613</td>
</tr>
<tr>
<td>TACR1</td>
<td>rs881</td>
<td>C</td>
<td>272</td>
<td>607</td>
</tr>
</tbody>
</table>

SNP, Single-nucleotide polymorphisms; MMSE, Mini-Mental State Examination.
opioid effects (Somogyi et al. 2007; Klepstad 2010; Barratt et al. 2014) prompted us to analyze a subgroup of patients receiving high opioid doses. We expected that associations between cognitive dysfunction and SNPs in genes of patients treated with morphine equivalent doses ≥400 mg/day could be found; however, that proved not to be the case. A too small sample size based on a reduced number of patients on high opioid doses may have played a role for the negative outcomes. It is interesting to note that a former study regarding opioid efficacy in the total sample of opioid-treated patients in the EPOS study did not show significant associations between genetic variability and opioid dosage (Klepstad et al. 2011).

**Strengths and limitations**

Strengths of this study include large sample size, diversity of included patients with cancer on opioid treatment, investigation of genes that were reported by the literature to have some relationship with cognitive function, and robust methods of analysis involving three genetic models and removal of false positives. On the other hand, several factors may have hampered the identification of genetic variability related to cognitive function. First, the mechanisms influencing cognitive function are complex and many variables such as medication, psychiatric/psychological disorders, and disease may influence the performance on different neuropsychological tests not related to genetic variation (Kendler and Neale 2010). Second, there exist several neuropsychological tests to assess different cognitive domains and consensus regarding the best instrument for each domain in this particular population is still under development. In this study MMSE was selected due to brevity and easy application, extensive use in research and clinical practice (Folstein et al. 1984; Crum et al. 1993), and its status as the “golden standard” instrument to measure cognitive function in patients with cancer (Meyers and Wefel 2003). However, criticism of MMSE includes rough measurement properties of cognition and psychometric limitations in nondemented popu-

### Table 4. SNPs associated with MMSE score among patients receiving daily oral morphine equivalent doses of 400 mg or more (n = 300).

<table>
<thead>
<tr>
<th>Gene</th>
<th>SNP</th>
<th>Minor allele</th>
<th>Discovery sample (n = 202)</th>
<th>Validation sample (n = 98)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Genotype frequency</td>
<td>MMSE score (median)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Genotype frequency</td>
<td>MMSE score (median)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Co-dominant</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TNRFSF1B</td>
<td>rs3397</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TLR5</td>
<td>rs5744168</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HTR2A</td>
<td>rs6311</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ADRA2A</td>
<td>rs11195419</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Dominant</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TACR1</td>
<td>rs2160652</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HTR2A</td>
<td>rs6311</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>TLR5</td>
<td>rs5744168</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ADRA2A</td>
<td>rs11195419</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Recessive</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GABBR2</td>
<td>rs2779562</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>HTR3E</td>
<td>rs6443950</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>IL6</td>
<td>rs2069835</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ADRA2A</td>
<td>rs553668</td>
</tr>
</tbody>
</table>

SNP, Single-nucleotide polymorphisms; MMSE, Mini-Mental State Examination.
cognitive function and ethnic background (Goldstein et al. 2014). Moreover, protective measures as intake of nonsteroidal anti-inflammatory drugs seem to slow down development of neurological diseases as Alzheimer’s disease and prevent cognitive decline in subjects with apolipoprotein E (APOE) e4 alleles (Hayden et al. 2007; Gorelick 2010).

Therefore, suggestions for future research in this area should consider the multifactorial nature of cognitive dysfunction and a proper study design. A better understanding of the issue, besides involving genetic aspects (exploration of other sets of genes, combined genes effects, mRNA levels, and polygenic analyses), should also consider several other variables related to cancer. The variety of potential causes for cognitive dysfunction includes known variables in the cancer population (e.g., socio-demographics, comorbidities, treatment, etc.), information from other conditions (e.g., inflammation biomarkers, dementia structural brain changes, neurodegeneration in older age, etc.), and variables not explored, but involving a plausible hypothesis (e.g., genes analyzed in animal studies). In addition, larger cohorts with adequate sample size and better methods of cognitive assessment are essential to provide high-quality data and possible definite answers.

In conclusion, the findings of this study did not support influence of those SNPs analyzed to explain cognitive dysfunction in this sample of patients. Several factors may have played a role blurring the potential identification of significant associations. Nonetheless, to the best of our knowledge, this is the first study to explore genetic variability and cognitive dysfunction in opioid-treated patients with cancer. Larger multicenter collaboration and interest of funding institutions are highly required for further investigation.

Acknowledgments

This study was supported by European Palliative Care Research Collaborative 6th EU Framework Programme and Norwegian Research Council. The authors have worked independently at all stages of the study, including design, data collection, analysis, data interpretation, preparation, and revision of the manuscript. There are no conflicts of interest.

Conflict of Interest

None declared.

References


